1. Kahne D, Leimkuhler C, Lu W, Walsh C. Glycopeptide and lipoglycopeptide antibiotics. Chem Rev. 2005;105(2):425–48.
2. Henson KE, Levine MT, Wong EA, Levine DP. Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile. Expert Rev Anti-infect Ther. 2015;12:1–14.
3. Nunn MO, Corallo CE, Aubron C, Poole S, Dooley MJ, Cheng AC. Vancomycin dosing: assessment of time to therapeutic concentration and predictive accuracy of pharmacokinetic modeling software. Ann Pharmacother (Research Support, Non-U.S. Gov’t). 2011;45(6):757–63.
4. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis: Off Publ Infect Dis Soc Am (Practice Guideline Research Support, Non-U.S. Gov’t). 2011;52(3):285–92.
5. Smith WJ, Drew RH. Telavancin: a new lipoglycopeptide for gram-positive infections. Drugs Today (Barc) (Review). 2009;45(3):159–73.